keyword
hemophagocyt
lymphohistiocytosi
r
hladr
r
perforin
r
primari
hlh
r
secondari
hlh
r
tcell
activ
addit
support
inform
may
found
onlin
version
articl
publish
websit
hemophagocyt
lymphohistiocytosi
hlh
hyperinflammatori
syndrom
current
defin
number
clinic
laboratori
featur
develop
context
variou
diseas
third
patient
hlh
monogenet
predisposit
affect
lymphocyt
cytotox
includ
famili
hemophagocyt
syndrom
sever
albin
syndrom
immunodefici
ch
xlink
lymphoprolif
syndrom
condit
summar
ebv
infect
key
trigger
hlh
syndrom
xlp
ebv
viral
bacteri
infect
also
trigger
diseas
patient
fhl
albin
syndrom
howev
fhl
patient
age
one
year
routin
microbiolog
investig
detect
infecti
agent
german
cohort
therefor
remain
unclear
trigger
requir
diseas
manifest
patient
two
third
hlh
case
clear
genet
predisposit
identifi
apart
patient
inborn
error
metabol
primari
immunodefici
possibl
contribut
monoallel
mutat
fhl
associ
gene
remain
debat
ammann
et
al
prepar
quarter
patient
underli
diseas
associ
immun
activ
autoimmun
autoinflammatori
diseas
malign
case
infect
particular
virus
frequent
addit
diseas
trigger
secondari
hlh
induc
variou
infect
promin
ebv
leishmania
without
obviou
underli
diseas
respons
addit
case
remain
quarter
german
cohort
neither
clear
diseaseassoci
condit
trigger
infect
report
ammann
et
al
prepar
hyperactiv
lymphocyt
histiocyt
eponym
featur
hlh
reflect
infiltr
cell
macrophag
hlh
target
organ
liver
bone
marrow
brain
well
detect
excess
level
inflammatori
cytokin
produc
cell
studi
perforin
knockout
mice
shown
cell
mainli
cell
critic
diseas
pathogenesi
cell
popul
significantli
activ
virusinfect
mice
genet
defect
cytotox
virusinfect
control
studi
defin
tcell
hyperactiv
key
featur
provid
rational
treatment
approach
mainli
target
activ
cell
atg
etoposid
alemtuzumab
remain
far
clear
howev
whether
activ
cell
import
elev
frequent
taken
indirect
evid
tcell
activ
hlh
also
shed
cell
includ
nonhematopoet
cell
correl
cellular
marker
tcell
activ
remain
examin
hypothes
activ
differenti
phenotyp
tcell
popul
differ
human
hlh
variant
may
mirror
involv
diseas
pathogenesi
underli
defect
cytotox
may
lead
phenotyp
footprint
tcell
compart
furthermor
pattern
tcell
activ
may
differ
virustrigg
noninfectionassoci
hlh
henc
analyz
marker
tcell
activ
differenti
patient
comparison
patient
noninfect
associ
patient
virustrigg
show
despit
similar
cell
activ
profil
cell
uniqu
signatur
may
indic
differ
pathogenesi
recruit
patient
fulfil
least
clinic
hlh
criteria
studi
support
inform
tabl
patient
classifi
includ
patient
patient
patient
patient
two
patient
patient
ch
three
patient
proven
viral
infect
two
ebv
one
cmv
thirti
patient
classifi
without
infect
includ
patient
ma
patient
metabol
diseas
patient
osteopetrosi
mutat
perforin
patient
could
assign
clear
underli
diseas
thirtytwo
patient
classifi
underli
diseas
among
patient
evid
acut
ebv
infect
serolog
andor
pcr
acut
viral
infect
diagnos
context
hlh
pcr
includ
cmv
adenoviru
coronaviru
parainfluenza
hsv
rsv
two
patient
posit
pcr
two
virus
ebvcmv
support
inform
tabl
hladr
express
cell
level
chemoluminesc
serum
measur
patient
sinc
agedepend
variabl
hladr
express
level
healthi
donor
limit
investig
includ
patient
younger
one
year
extens
variabl
tcell
differenti
marker
express
beyond
age
human
cell
express
mhc
class
ii
molecul
hladr
tcr
mediat
activ
well
number
cytokin
particular
type
type
ii
interferon
also
gmcsf
upregul
hladr
express
analyz
hladr
express
cell
patient
activ
hlh
n
absenc
immunosuppress
therapi
includ
patient
n
n
without
document
viral
infect
n
summar
tabl
irrespect
age
healthi
donor
show
hladr
express
percentag
hladr
cell
among
total
cell
upper
panel
hladr
cell
among
total
cell
lower
panel
indic
group
patient
differ
three
group
analyz
mannwhitney
u
test
signific
differ
shown
defin
p
p
c
roc
curv
show
cutoff
optim
sensit
specif
hladr
upper
panel
cell
lower
panel
patient
form
hlh
control
serum
level
solubl
measur
chemiluminesc
immunoassay
clia
patient
n
n
n
given
uml
differ
three
group
analyz
mannwhitney
u
test
mean
sd
shown
signific
differ
shown
defin
p
p
cell
fig
proport
cell
increas
hladr
express
significantli
higher
patient
hlh
among
cell
moder
mean
patient
absenc
appar
infect
much
higher
median
patient
trigger
viru
infect
well
patient
mean
fig
upper
panel
tcell
activ
significantli
differ
patient
ebvassoci
hlh
patient
hlh
context
viral
infect
data
shown
interestingli
pattern
hladr
express
differ
among
cell
show
moder
increas
fraction
hladr
express
cell
group
patient
mean
much
higher
mean
patient
fig
lower
panel
perform
roc
analysi
determin
cutoff
optim
sensit
specif
hladr
discrimin
healthi
donor
patient
form
activ
hlh
percentag
hladr
express
among
cell
among
cell
achiev
sensit
specif
well
howev
hladr
express
could
differenti
fig
increas
serum
level
solubl
receptor
chain
characterist
marker
immun
activ
hlh
shed
activ
cell
also
express
nk
cell
b
cell
macrophag
dendrit
cell
nonimmun
cell
fibroblast
pulmonari
endotheli
cell
therefor
remain
unclear
extent
level
reflect
tcell
activ
differ
hlh
condit
serum
level
highli
elev
three
group
patient
howev
patient
significantli
higher
serum
level
uml
compar
group
fig
unexpectedli
poor
correl
hladr
express
cell
level
patient
group
fig
e
f
signific
correl
observ
fraction
hladr
cell
level
patient
fig
poor
correl
could
either
explain
fact
look
percentag
circul
cell
absolut
number
includ
activ
cell
lymphoid
tissu
point
sourc
cell
address
question
whether
differ
hladr
express
reflect
tcell
differenti
pattern
differ
subtyp
hlh
accord
appay
cell
defin
central
memori
cell
tcm
effectormemori
tem
cell
termin
differenti
effector
te
cell
fig
sinc
variabl
percentag
memori
cell
increas
age
restrict
analysi
patient
control
younger
one
year
age
support
inform
tabl
patient
without
appar
infect
n
cell
similar
healthi
control
asymptomat
patient
contrast
major
cell
effectormemori
phenotyp
patient
patient
n
advanc
tcell
differenti
less
pronounc
among
cell
predomin
effectormemori
phenotyp
observ
patient
notabl
pronounc
patient
fig
overal
pattern
tcell
activ
variabl
differ
individu
support
inform
fig
probabl
favor
fact
sampl
taken
differ
time
point
cours
diseas
two
promin
phenotyp
chang
tcell
activ
downregul
receptor
alpha
chain
upregul
inhibitori
receptor
consist
result
obtain
patient
without
viral
trigger
low
percentag
express
cell
similar
healthi
donor
asymptomat
patient
fig
contrast
patient
patient
percentag
well
cell
highli
increas
fig
ad
chang
tcell
popul
pronounc
although
differ
reach
statist
signific
express
fig
epitop
human
cell
strongli
correl
prolif
histori
cell
produc
cytokin
cytotox
poorli
prolifer
vitro
expect
almost
cell
detect
healthi
infant
asymptomat
patient
similar
patient
fig
ef
contrast
cell
increas
patient
virusinduc
particularli
fig
among
cell
express
cell
significantli
higher
compar
note
infant
classifi
without
appar
microbi
trigger
littl
evid
tcell
activ
hladr
differenti
marker
despit
fact
fulfil
current
clinic
diagnost
hlh
includ
level
uml
perforin
express
mainli
induc
activ
cell
also
detect
termin
differenti
human
cell
chronic
infect
analyz
perforin
express
patient
cohort
besid
infant
degranul
defect
also
includ
patient
biallel
perforin
mutat
reduc
suffici
residu
protein
express
separ
perforinposit
perforinneg
cell
proport
perforin
express
cell
low
control
variabl
elev
patient
irrespect
viral
trigger
fig
b
highest
proport
perforinexpress
ctl
observ
patient
differ
much
pronounc
compart
fig
perforinposit
cell
particular
cell
usual
character
downregul
interestingli
among
infant
cell
repres
perforin
popul
shown
patient
mix
phenotyp
fig
indic
cell
repres
earlyintermedi
differenti
acut
effector
cell
strong
antigenspecif
activ
cell
result
repertoir
alter
due
preferenti
expans
antigenspecif
tcell
popul
analyz
tcell
receptor
repertoir
hlh
patient
use
antibodi
common
tcr
vbeta
chain
patient
classifi
without
appar
infecti
trigger
show
v
beta
repertoir
among
cell
similar
control
infant
fig
compar
control
patient
v
beta
chain
popul
repres
standard
deviat
mean
normal
donor
mean
sd
indic
moder
perturb
normal
repertoir
pictur
similar
patient
singl
patient
found
strong
domin
v
beta
express
tcell
popul
fig
tcr
repertoir
analysi
reveal
obviou
gener
differ
character
pattern
immun
activ
patient
differ
form
hlh
perform
phenotyp
comparison
tcell
compart
observ
summar
tabl
support
three
main
conclus
first
tcell
activ
hallmark
mani
defin
form
hlh
promin
also
form
includ
ma
howev
diseas
state
meet
current
diagnost
criteria
syndrom
hlh
occur
without
obviou
evid
tcell
activ
second
pattern
tcell
activ
case
appar
absenc
microbi
trigger
similar
trigger
viral
infect
third
strong
activ
cytotox
cell
signatur
much
less
pronounc
virustrigg
find
relev
understand
pathogenesi
differ
hlh
variant
implic
differenti
diagnosi
previou
studi
report
increas
hladr
express
cell
mild
decreas
percentag
cell
children
activ
hlh
howev
analyz
larger
cohort
clearli
defin
diseas
subtyp
current
possibl
confirm
genet
diseas
observ
strong
activ
tcell
compart
patient
less
pronounc
patient
absenc
infect
includ
patient
ma
infant
diseas
state
fulfil
current
clinic
criteria
even
occur
absenc
measur
tcell
activ
patient
activ
polyclon
mild
perturb
normal
repertoir
larg
fraction
cell
effector
memori
phenotyp
associ
downregul
upregul
hladr
perforin
differenti
pattern
similar
virusspecif
cell
patient
undergo
acut
viru
infect
absenc
hlh
cmv
infect
percentag
cell
correl
level
viral
replic
incomplet
viru
control
increas
fraction
cell
defin
cell
high
lytic
granul
content
cytotox
activ
thu
cell
phenotyp
highli
repres
hladr
perforin
phenotyp
also
observ
patient
highli
activ
uncontrol
viral
infect
absenc
featur
hlh
interestingli
howev
studi
infant
proven
concomit
viral
infect
apart
patient
periungu
aureu
infect
bacteri
opportunist
infect
detect
less
expect
previous
report
cohort
patient
hlh
patient
posit
famili
histori
report
infecti
trigger
obvious
although
patient
extens
search
system
viral
infect
includ
ebv
cmv
adenoviru
parvoviru
perform
investig
rule
infect
particularli
respiratori
gastrointestin
virus
unclear
howev
whether
local
infect
without
system
spread
suffici
trigger
maintain
strong
system
tcell
activ
observ
least
perforindefici
pko
mice
system
persist
infect
lcmv
mcmv
induc
hlh
local
infect
respiratori
virus
rsv
pneumonia
viru
mice
influenza
caus
hlh
pko
mice
overal
therefor
remain
relev
possibl
highli
activ
tcell
phenotyp
observ
human
case
driven
persist
viral
microbi
infect
would
impli
human
perforinmedi
control
tcell
stimul
requir
mainten
tcell
homeostasi
even
absenc
continu
viral
stimul
pathophysiolog
differ
also
suggest
differ
pattern
cell
activ
two
condit
percentag
cell
highli
activ
hladr
perforin
phenotyp
higher
although
perforinexpress
cell
cytotox
activ
describ
persist
viru
infect
hiv
ebv
cmv
infect
none
condit
cell
reach
level
observ
primari
hlh
stronger
activ
cell
suggest
qualit
differ
activ
tcell
popul
thu
cytotox
defect
associ
impair
elimin
stimul
apc
could
favor
addit
recruit
cell
inflammatori
respons
prolong
present
antigen
via
mhc
class
ii
function
cytotox
cell
specul
play
role
contain
viral
infect
tropic
mhc
class
ii
posit
cell
ebv
b
cell
could
also
take
promin
role
antivir
respons
pathogen
evolv
mechan
evad
antigen
present
mhc
class
molecul
howev
view
consider
also
conceiv
cytotox
cell
role
human
tcell
homeostasi
independ
infect
control
eg
control
apc
relev
number
infant
without
cytotox
defect
fulfil
current
diagnost
criteria
hlh
absenc
infect
mostli
naiv
cell
cell
express
marker
activ
advanc
differenti
level
rang
uml
well
known
immun
cell
cell
well
nonimmun
cell
significantli
contribut
product
fact
recent
document
similar
level
immunodefici
patient
fulfil
clinic
hlh
criteria
complet
lack
nk
cell
current
studi
formal
label
patient
discuss
previous
question
whether
hemophagocyt
inflammatori
syndrom
patient
realli
call
hlh
studi
illustr
current
clinic
criteria
hlh
differenti
cell
driven
diseas
bona
fide
hlh
hemophagocyt
syndrom
without
tcell
activ
obviou
implic
therapi
particular
target
cell
revis
prospect
valid
diagnost
criteria
need
data
suggest
inclus
marker
tcell
activ
consid
use
may
help
avoid
aggress
treatment
patient
accord
current
criteria
inappropri
classifi
suffer
lymphocyt
histiocytosi
patient
recruit
project
hlh
studi
german
societi
pediatr
hematolog
oncolog
detail
describ
elsewher
ammann
et
al
prepar
studi
carri
obtain
institut
review
board
approv
univers
freiburg
ethic
committe
protocol
number
control
sampl
healthi
donor
year
age
obtain
clinic
hiv
expos
infect
infant
ethic
number
patient
inclus
requir
activ
hlh
time
blood
sampl
ie
least
criteria
defin
histiocyt
societi
patient
receiv
steroid
day
patient
receiv
cyclosporin
etoposid
exclud
patient
microbiolog
investig
recommend
includ
blood
cultur
screen
ebv
cmv
adenoviru
parvoviru
serolog
pcr
extent
investig
control
studi
describ
ammann
et
al
prepar
patient
degranul
assay
fresh
uncultur
activ
incub
uml
h
nk
cell
parallel
stain
perforin
sap
xiap
express
perform
dna
patient
abnorm
protein
express
sequenc
mutat
patient
abnorm
degranul
analyz
includ
select
intron
region
patient
albin
sequenc
lyst
exom
sequenc
perform
unresolv
case
defect
fresh
nk
degranul
describ
patient
reduc
perforin
express
defect
nk
cell
degranul
biallel
mutat
gene
associ
ch
classifi
patient
xlp
malign
diseas
exclud
patient
neg
genet
result
includ
patient
monoallel
variant
immunolog
abnorm
patient
genet
analysi
perform
classifi
diseas
relaps
least
month
first
hlh
episod
median
followup
year
among
patient
develop
hlh
context
document
viral
infect
classifi
hlh
patient
develop
hlh
without
underli
diseas
without
evid
infect
classifi
patient
could
clearli
assign
one
group
exclud
sibl
identifi
birth
biallel
mutat
hlhassoci
gene
without
clinic
symptom
includ
control
possibl
alter
cell
phenotyp
due
genet
defect
absenc
acut
hlh
episod
asymptomat
group
hiv
expos
infect
infant
year
age
includ
healthi
control
hladr
express
cell
level
chemiluminesc
immunoassay
clia
measur
patient
refer
suspect
hlh
sinc
ageindepend
variabl
hladr
express
level
healthi
donor
limit
patient
age
fulfil
inclus
criteria
consid
analysi
n
investig
includ
patient
younger
one
year
extens
variabl
tcell
differenti
marker
express
beyond
age
group
ficol
isol
pbmc
stain
three
differ
stain
use
antibodi
indic
support
inform
materi
data
analyz
mannwhitney
u
test
use
graphpad
prism
version
window
graphpad
softwar
san
diego
california
usa
wwwgraphpad
signific
defin
p
p
p
p
author
would
like
thank
patient
famili
well
physician
particip
gpoh
hlh
studi
grate
team
cci
advanc
diagnost
unit
excel
work
work
support
grant
dfg
bmbf
eo
se
follow
physician
contribut
substanti
